Novo Nordisk's success with its GLP-1 receptor agonists, Ozempic and Wegovy, is examined, highlighting the
intense competition in the weight-loss drug market. The text explores
various factors influencing the company's dominance, including
market demand driven by the obesity epidemic,
regulatory hurdles and pricing strategies, and
internal factors such as strong R&D and strategic alignment.
Technological advancements and
social trends also played crucial roles. Despite
side effects and high costs, the drugs' effectiveness has fueled significant demand.